Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rat (SHR): implications for cognitive deficits in a progressive animal model for Parkinson’s Disease

Full metadata record
DC FieldValueLanguage
dc.contributorLab. Farmacologiapt_BR
dc.contributorUnidade de Modo de Ação de Toxinaspt_BR
dc.contributor.authorLeão, Anderson H.F.F.pt_BR
dc.contributor.authorMeurer, Ywlliane S.R.pt_BR
dc.contributor.authorFreitas, Thalma A.pt_BR
dc.contributor.authorMedeiros, André M.pt_BR
dc.contributor.authorAbílio, Vanessa C.pt_BR
dc.contributor.authorIzídio, Geison S.pt_BR
dc.contributor.authorConceição, Isaltino Marcelopt_BR
dc.contributor.authorRibeiro, Alessandra M.pt_BR
dc.contributor.authorSilva, Regina H.pt_BR
dc.date.accessioned2021-05-14T18:33:44Z-
dc.date.available2021-05-14T18:33:44Z-
dc.date.issued2021pt_BR
dc.identifier.citationLeão AH.F.F., Meurer YS.R., Freitas TA., Medeiros AM., Abílio VC., Izídio GS., et al. Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rat (SHR): implications for cognitive deficits in a progressive animal model for Parkinson’s Disease. Behav Brain Res. 2021 May;410:113349. doi:10.1016/j.bbr.2021.113349.pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/3731-
dc.description.abstractReserpine (RES) is an irreversible inhibitor of VMAT2 used to study Parkinson’s disease (PD) and screening for antiparkinsonian treatments in rodents. Recently, the repeated treatment with a low dose of reserpine was proposed as a model capable of emulating progressive neurochemical, motor and non-motor impairments in PD. Conversely, compared to Wistar rats, Spontaneously Hypertensive Rats (SHR) are resistant to motor changes induced by repeated treatment with a low dose of RES. However, such resistance has not yet been investigated for RES-induced non-motor impairments. We aimed to assess whether SHR would have differential susceptibility to the object recognition deficit induced by repeated low-dose reserpine treatment. We submitted male Wistar and SHR rats to repeated RES treatment (15 s.c. injections of 0.1 mg/kg, every other day) and assessed object memory acquisition and retrieval 48 h after the 6th RES injection (immediately before the appearance of motor impairments). Only RES Wistar rats displayed memory impairment after reserpine treatment. On the other hand, untreated SHR rats displayed object recognition memory deficit, but RES treatment restored such deficits. We also performed immunohistochemistry for tyrosine hydroxylase (TH) and α-synuclein (α-syn) 48 h after the last RES injection. In a different set of animals submitted to the same treatment, we quantified DA, 5-HT and products of lipid peroxidation in the prefrontal cortex (PFC) and hippocampus (HPC). SHR presented increased constitutive levels of DA in the PFC and reduced immunoreactivity to TH in the medial PFC and dorsal HPC. Corroborating the behavioural findings, RES treatment restored those constitutive alterations in SHR. These findings indicate that the neurochemical, molecular and genetic differences in the SHR strain are potentially relevant targets to the study of susceptibility to diseases related to dopaminergic alterations.pt_BR
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)pt_BR
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)pt_BR
dc.description.sponsorshipFundação de Apoio à Pesquisa do Rio Grande do Norte (FAPERN)pt_BR
dc.description.sponsorshipPró-reitoria De Pesquisa da Universidade Federal do Rio Grande do Norte (PROPESQ/UFRN)pt_BR
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)pt_BR
dc.format.extent113349pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofBehavioural Brain Researchpt_BR
dc.rightsRestricted Accesspt_BR
dc.titleChanges in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rat (SHR): implications for cognitive deficits in a progressive animal model for Parkinson’s Diseasept_BR
dc.typeArticlept_BR
dc.identifier.doi10.1016/j.bbr.2021.113349pt_BR
dc.identifier.urlhttps://doi.org/10.1016/j.bbr.2021.113349pt_BR
dc.contributor.externalUniversidade Federal de São Paulo (UNIFESP)pt_BR
dc.contributor.externalUniversidade Federal da Paraíba (UFPB)pt_BR
dc.contributor.externalUniversidade Federal Rural do Semi-Arido (UFERSA)pt_BR
dc.contributor.externalNational Institute for Translational Medicine (INCT-TM)pt_BR
dc.contributor.externalUniversidade Federal de Santa Catarinapt_BR
dc.identifier.citationvolume410pt_BR
dc.subject.keyworddopaminept_BR
dc.subject.keywordnovel object recognitionpt_BR
dc.subject.keywordparkinsonismpt_BR
dc.subject.keywordtyrosine hydroxylasept_BR
dc.subject.keywordalpha-synucleinpt_BR
dc.relation.ispartofabbreviatedBehav Brain Respt_BR
dc.identifier.citationabntv. 410, 113349, maio. 2021pt_BR
dc.identifier.citationvancouver2021 May;410:113349pt_BR
dc.contributor.butantanConceição, Isaltino Marcelo|:Pesquisador|:Lab. Farmacologia:Unidade de Modo de Ação de Toxinaspt_BR
dc.sponsorship.butantanConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)¦¦pt_BR
dc.sponsorship.butantanCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)¦¦pt_BR
dc.sponsorship.butantanFundação de Apoio à Pesquisa do Rio Grande do Norte (FAPERN)¦¦pt_BR
dc.sponsorship.butantanPró-reitoria De Pesquisa da Universidade Federal do Rio Grande do Norte (PROPESQ/UFRN)¦¦pt_BR
dc.sponsorship.butantanFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)¦¦2015/12308-5pt_BR
dc.sponsorship.butantanFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)¦¦2015/03354-3pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.grantfulltextembargo_29990101-
item.languageiso639-1English-
item.openairetypeArticle-
item.fulltextCom Texto completo-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0003-2392-8103-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos de periódicos


Files in This Item:

Existing users please Login
10.1016j.bbr.2021.113349.pdf
Description:
Size: 4.26 MB
Format: Adobe PDF
Embargoed until January 1, 2999    Request a copy
Show simple item record

The access to the publications deposited in this repository respects the licenses from journals and publishers.